| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
1
Stanford University Medical School, Department of Cardiovascular Medicine, Stanford, CA 94305-5406.
2
University Hospital Eppendorf, Department of Cardiology,
20246 Hamburg, Germany.
3
Kerckhoff-Clinic, Department of Cardiology, 61231 Bad
Nauheim, Germany.
a Author for correspondence. Fax 650-725-1599; e-mail heeschen{at}stanford.edu
Background: Troponin I (cTnI) provides important prognostic information in patients with chest pain. We wished to evaluate a rapid, whole-blood analyzer for quantitative point-of-care testing.
Methods: A quantitative point-of-care test system (Stratus CS®; Dade-Behring) for cTnI with an incorporated centrifuge was evaluated in 412 patients with chest pain less than 12 h.
Results: Results were available within 15 min. CVs were 4.5% at
0.1 µg/L, 4.2% at 0.25 µg/L, and 6.5% at 0.82 µg/L. The
detection limit was 0.01 µg/L. The 97.5% percentile in a
healthy population was 0.08 µg/L. Based on ROC curve analysis,
a threshold of 0.15 µg/L was calculated for the detection of acute
myocardial infarction (AMI). With it, sensitivity for the detection of
patients with AMI (n = 62) was 63% at arrival and 98% after
4 h (Stratus II®, 48% and 85%, respectively;
P <0.01). In 42% of patients with unstable angina
(n = 121), cTnI was 
0.08 µg/L (Stratus II, 28%;
P <0.01). During 30 days, death or AMI occurred in
25.5% of these cTnI-positive vs 2.9% of cTnI-negative patients
(Stratus II, 29.4% vs 5.8%).
Conclusion: The Stratus CS provided better analytical performance and comparable or better prognostic information than the Stratus II.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  C. Heeschen, S. Dimmeler, C. W. Hamm, E. Boersma, A. M. Zeiher, M. L. Simoons, and on Behalf of the CAPTURE (c7E3 Anti-Platelet Thera Prognostic Significance of Angiogenic Growth Factor Serum Levels in Patients With Acute Coronary Syndromes Circulation, February 4, 2003; 107(4): 524 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. Sandri, D. Cardinale, L. Zorzino, R. Passerini, P. Lentati, A. Martinoni, G. Martinelli, and C. M. Cipolla Minor Increases in Plasma Troponin I Predict Decreased Left Ventricular Ejection Fraction after High-Dose Chemotherapy Clin. Chem., February 1, 2003; 49(2): 248 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Kim, O. F. Laterza, K. G. Hock, J. F. Pierson-Perry, D. M. Kaminski, M. Mesguich, F. Braconnier, R. Zimmermann, M. Zaninotto, M. Plebani, et al. Performance of a Revised Cardiac Troponin Method That Minimizes Interferences from Heterophilic Antibodies Clin. Chem., July 1, 2002; 48(7): 1028 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Venge, B. Lindahl, and L. Wallentin New Generation Cardiac Troponin I Assay for the Access Immunoassay System Clin. Chem., May 1, 2001; 47(5): 959 - 961. [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Chapelle, M.-C. Aldenhoff, L. Pierard, and J. Gielen Comparison of Cardiac Troponin I Measurements on Whole Blood and Plasma on the Stratus CS Analyzer and Comparison with AxSYM Clin. Chem., November 1, 2000; 46(11): 1864 - 1866. [Full Text] [PDF]
|
|
|
|
|
|
F. S. Apple, F. P. Anderson, P. Collinson, R. L. Jesse, M. C. Kontos, M. A. Levitt, E. A. Miller, and M. M. Murakami Clinical Evaluation of the First Medical Whole Blood, Point-of-Care Testing Device for Detection of Myocardial Infarction Clin. Chem., October 1, 2000; 46(10): 1604 - 1609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Altinier, M. Mion, A. Cappelletti, M. Zaninotto, and M. Plebani Rapid Measurement of Cardiac Markers on Stratus CS Clin. Chem., July 1, 2000; 46(7): 991 - 993. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
